A Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy With Dose Escalation to 54 Gy With Concurrent Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Long-Term Results at a Single Institution

Lung Cancer

Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study

Sci Rep

Wang L, Wang R, Wei Z, Wang Y, Chen H, Dong B, Hu X, Ma H, Wang Z, Feng W, Li P, Lin X, Xu Y

doi: 10.1038/s41598-024-73177-2

RECOMMENDED

Lung Cancer

The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N

doi: 10.1016/j.cllc.2025.02.002

RECOMMENDED

Lung Cancer

The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results

★ 1 Recommended by Dr Martin Frey, Faculty Member

Clin Lung Cancer

Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A

doi: 10.1016/j.cllc.2025.07.003

Lung Cancer

Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

Clin Lung Cancer

Reinmuth N, Goldman JW, Chen Y, Hotta K, Trukhin D, Statsenko G, Hochmair M, Özgüroğlu M, Ji JH, Garassino MC, Poltoratskiy A, Verderame F, Havel L, Bondarenko I, Losonczy G, Conev N, Kummer S, Mann H, Chugh P, Dalvi T, Paz-Ares L

doi: 10.1016/j.cllc.2025.08.001

Lung Cancer

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

Lancet Respir Med

Asao T, Saida Y, Watanabe S, Kisohara A, Kishi K, Morita R, Nakagawa T, Tsukita Y, Furuya N, Miyawaki T, Ishikawa N, Yamada T, Tanaka T, Morita S, Kikuchi T, Maemondo M, Kobayashi K, North East Japan Study Group

doi: 10.1016/S2213-2600(25)00240-1

RECOMMENDED

Lung Cancer

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial

★ 1 Recommended by Dr Martin Frey, Faculty Member

Nat Commun

Bian D, Ji S, Liu Y, Huang Z, Jiang L, Liu M, Bao X, Yang J, Zhou Y, Hu J, Sun L, Zheng Y, Huang J, Liu J, Zhu X, Zhang J, Zhang L, Liu X, He W, Xie D, Zhu Y, Wu C, Zhao D, Duan L, Jiang G, Zhang P

doi: 10.1038/s41467-025-58435-9

Lung Cancer

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

Lung Cancer

Isla D, Zugazagoitia J, Arriola E, García-Campelo R, Martí Blanco C, Diz-Taín MP, López-Brea M, Moreno-Vega AL, León-Mateos L, Oramás J, Gutiérrez-Calderón V, Majem M, Sánchez-Hernández A, Aguado C, Alvarez-Cabellos R, Massutí B, Moreno A, Fírvida-Pérez JL, Valdivia J, González-Cordero M, Zafra-Poves M, Dómine M, Garcia-Navalon FJ, Villanueva N, Provencio M, Juan-Vidal O, Rivas-Corredor C, Olmedo García ME, Palmero R, López-Castro R, Carcereny E, Lechuga JL, Domínguez M, Callejo Á, Paz-Ares L

doi: 10.1016/j.lungcan.2025.108763

Lung Cancer

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Clin Lung Cancer

Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM

doi: 10.1016/j.cllc.2025.05.014

RECOMMENDED

Lung Cancer

Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort

★ 2 Recommended by Dr Martin Frey, Faculty Member

★ 3 Recommended by Dr Marcus Hesse, Faculty Member

J Clin Med

Lopez I, Aguinagalde B, Ferrer-Bonsoms JA, Sánchez L, Ascanio F, Sesma J, Recuero JL, Fernandez-Monge A, Lizarbe JA, Embun R

doi: 10.3390/jcm14072267

Related content

Long-term survival and failure patterns in inoperable early-stage non-small cell lung cancer following stereotactic body radiotherapy: a single-institution retrospective study

The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan

The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results

Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial

Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial

A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)

Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort